Table of contents
September 2022 - Volume 93 - 9
Occasional essay
Neurodegeneration
Cerebrovascular disease
Movement disorders
Multiple sclerosis
Neuromuscular
Neuropsychiatry
Sleep disorders
PostScript
Electronic page
- Acute inflammatory CNS diseases following vaccination against SARS-CoV-2 (12 August, 2022)
- Epilepsy mortality in Wales during COVID-19 (12 August, 2022)
- A novel neurodegenerative disease with multi-system features (12 August, 2022)
- West is best – a strongman with numb feet (12 August, 2022)
- An astra-nomical headache (12 August, 2022)
- Changing phenotypes, a spectrum over 10 years (12 August, 2022)
- Case presentation competition|5 Back to basics (12 August, 2022)
- Cryptic confusion (12 August, 2022)
- 001 An unusual cause of lymphocytic meningitis (12 August, 2022)
- 002 Neuromyelitis optica or HIV: the chameleon strikes again? (12 August, 2022)
- 017 Neurology virtual clinic: quality improvement project (12 August, 2022)
- 023 Impact of pandemic on neurologists and neurology practice (12 August, 2022)
- 025 Croydon neurology: 5 years of novel service developments (12 August, 2022)
- 033 Extracranial-tumor cerebri (12 August, 2022)
- 034 Revolutionary cancer treatment a pyrrhic victory? (12 August, 2022)
- 035 Brain tumours and sociodemographic factors: a review (12 August, 2022)
- 036 A GWAS of LGI1-antibody encephalitis (12 August, 2022)
- 037 Apparent homozygous c.830G>A GNE myopathy in non-jewish Iraqi (12 August, 2022)
- 044 At what resolution does the brain perform computations? (12 August, 2022)
- 055 Assessment of MACE cognitive screener using efficiency indexes (12 August, 2022)
- 057 Dementia and sociodemographic factors a review (12 August, 2022)
- 063 The role of Monoclonal antibodies in contrasting cases of NORSE (12 August, 2022)
- 064 Epilepsy and sociodemographic factors a review (12 August, 2022)
- 065 Septal DNETs rarely cause seizures – consider other causes (12 August, 2022)
- 078 Bruns syndrome – broadening the phenotype (12 August, 2022)
- 081 Impact of co-morbid PCOS on IIH outcomes (12 August, 2022)
- 083 Intravenous magnesium for acute presentations of migraine to A&E (12 August, 2022)
- 084 Migraine and sociodemographic factors a review (12 August, 2022)
- 087 A rarity of a rare condition – do we have a HaNDL on it? (12 August, 2022)
- 097 Transcranial sonography in the prodromal phase of PD (12 August, 2022)
- 100 Antiphospholipid-related chorea (12 August, 2022)
- 101 Motor and non-motor features of prodromal PD (12 August, 2022)
- 102 Levodopa and melanoma what do clinicians think? (12 August, 2022)
- 105 A rare presentation of Bickerstaff’s brainstem encephalitis (12 August, 2022)
- 109 Embedding patient voice in trial design: the EJS ACT-PD experience (12 August, 2022)
- 112 Parkinson’s disease and sociodemographic factors: a review (12 August, 2022)
- 117 Who is the culprit – the virus or the anti-virus? (12 August, 2022)
- 121 The ADAMS project: protocol and baseline results (12 August, 2022)
- 124 Multiple sclerosisand sociodemographic factors a review (12 August, 2022)
- 129 Multiple sclerosis relapse patterns in a population-based cohort (12 August, 2022)
- 130 IgLON5-antibody disease: a case series (12 August, 2022)
- 133 Multiple sclerosis and the risk of infection: a consensus guideline (12 August, 2022)
- 134 Predictors of serum vitamin D level in multiple sclerosis (12 August, 2022)
- 155 Reasons for stopping MS disease modifying treatment in a UK cohort (12 August, 2022)
- 163 Immunosuppression guidelines ongoing implementation project (12 August, 2022)
- 164 The role of MEG in assessment and diagnosis in mTBI (12 August, 2022)
- 168 Traumatic brain injury and sociodemographic factors: a review (12 August, 2022)
- 171 Urinary P75: a novel biomarker for motor neuron disease? (12 August, 2022)
- 176 Motor fatigability in motor neuron disease (12 August, 2022)
- 177 An unusual presentation in motor neurone disease (12 August, 2022)
- 178 Motor neurone disease and sociodemographic factors: a review (12 August, 2022)
- 179 Impact inventory development in neurological pathways (12 August, 2022)
- 182 Pooled safety data from the risdiplam clinical development programme (12 August, 2022)
- 184 ROADS to remote monitoring of ALS (12 August, 2022)
- 188 SUNFISH 3-year efficacy and safety of risdiplam in types 2 and 3 SMA (12 August, 2022)
- 197 Checkpoint inhibitor associated neuritis a novel pathological entity (12 August, 2022)
- 201 A case report of Collet Sicard syndrome (12 August, 2022)
- 203 A case of post COVID-19 endotheliitis (12 August, 2022)
- 206 Stroke and sociodemographic factors: a review (12 August, 2022)
Editorial commentary